AcrySof® IQ PanOptix® Toric Trifocal IOL TFNT30 (REF TFNT30U100)Recalls & reported problems
Alcon Laboratories, Inc. · AcrySof® IQ PanOptix® Toric Trifocal intraocular lenses (IOLs) are ultraviolet absorbing and blue light filtering foldable multifocal IOLs · Class 3 · Implant
All models of AcrySof IQ PanOptix Toric Trifocal IOL (165)
Data updated Oct 16, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 2
- Deaths reported
- 0
- Injuries reported
- 2
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 00380652415323), received between Mar 13, 2022 and Feb 8, 2024 — classified as 2 injuries.
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.
Reports received per month
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem2
Patient problems
- Blurred Vision1
- Visual Disturbances1
- Visual Impairment1
Recent adverse event reports
The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.
InjuryFeb 8, 2024Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
A CONSUMER REPORTED THAT AN INTRAOCULAR LENS (IOL) IMPLANT PROCEDURE WAS NOT SUCCESSFUL AS DEPTH OF FOCUS MULTIFOCAL LENS WAS RECOMMENDED DESPITE, WHAT SHE HAD SINCE LEARNED WITH HER NEW DOCTOR WAS THERE BEING TWO CONTRAINDICATIONS THAT ACTUALLY MEANT SHE WAS NOT A CANDIDATE FOR SAID LENS. ADDITIONAL INFORMATION HAS BEEN REQUESTED, RECEIVED AND STATED THE CONSUMER HAD HISTORY OF RETINAL DETACHMENT (RD) W/ REPAIR TO OTHER EYE PRIOR TO CATARACT SURGERY AS WELL AS LATTICE DEGENERATION. SHE STATED DUE TO THE RD REPAIR HER PUPIL DOES NOT CONSTRICT OR DILATE NORMALLY. SHE SEES FUZZY IN ALL DISTANCES. LINES WERE NOT STRAIGHT BUT ISN'T SURE IF THAT'S FROM THE RD REPAIR OR FROM THE IMPLANTS. SHE HAD YTTRIUM ALUMINUM GARNETT (YAG) POSTERIOR CAPSULOTOMY. PATIENT NOW HAS TO WEAR GLASSES TO CORRECT VISION. THERE ARE TWO MEDICAL DEVICE REPORTS ASSOCIATED WITH THIS PATIENT. THIS REPORT IS ASSOCIATED WITH THE RIGHT EYE.
Patient problems: Blurred Vision; Visual Disturbances
MAUDE report 18667248 ↗InjuryMar 13, 2022Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
A CONSUMER REPORTED THAT FOLLOWING AN INTRAOCULAR LENS (IOL) IMPLANT PROCEDURE, CONSUMER NOT ABLE TO SEE SIGNS WELL ENOUGH TO DRIVE DAY OR NIGHT. ADDITIONAL INFORMATION HAS BEEN REQUESTED. THERE ARE TWO MEDICAL DEVICE REPORTS ASSOCIATED WITH THIS PATIENT. THIS REPORT IS ASSOCIATED WITH THE 1ST FILE.
Patient problems: Visual Impairment
MAUDE report 13751350 ↗
Other Lens, multifocal intraocular devices
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular144 reports
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular1 recall66 reports
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular113 reports
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular112 reports
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular110 reports
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular107 reports
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular104 reports
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular93 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 16, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page